Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AffaMed Approved to Start China Trial of Parkinson's Candidate

publication date: May 28, 2021

Shanghai AffaMed Therapeutics was approved to start a China Phase IIb trial of its Parkinson's Disease candidate. AM006 is a novel non-ergot dopamine agonist that acts by stimulating striatal dopamine receptors. Because AM006 has a higher affinity for dopamine receptors, and more balanced activation of D2 and D3 receptors, it is expected to show fewer side effects than other members the dopamine agonist class. In  2020, AffaMed acquired Greater China rights to the candidate from Kissei Pharma, a Japanese company. AffaMed will join the global Phase IIb trial of the molecule. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital